FDA Talk Papers are prepared by the Press Office to guide FDA personnel in responding with consistency and accuracy to questions from the public on subjects of current interest. Talk Papers are subject to change as more information becomes available.
| T02-19 | Media Inquiries: 301-436-2335 |
| April 12, 2002 | Consumer Inquiries: 888-INFO-FDA |
FDA today alerted health care professionals about the risk of Enterobacter sakazakii (E.sakazakii) infections in hospitalized newborn infants, particularly premature infants or other immuno-compromised infants fed powdered infant formulas. This alert issued by FDA is targeted to concerns for immuno-compromised infants in hospital settings. The FDA is not aware of E. sakazakii infections among healthy full term infants in home settings. In addition, this alert does not involve the use of liquid infant formulas.
E. sakazakii is an emerging foodborne pathogen that can cause sepsis, meningitis, or necrotizing enterocolitis in newborn infants, particularly premature infants or other infants with weakened immune systems. Over the last several years, investigations of several outbreaks of E. sakazakii infection occurring in neonatal intensive care units worldwide have shown the outbreak to be associated with milk-based powdered infant formulas.
Recently, the U. S. Centers for Disease Control and Prevention (CDC) investigated a fatal E. sakazakii meningitis case in a neonatal intensive care unit in the United States. According to the CDC, the use of milk-based powdered formula was a likely factor in the infection of this child. The details of CDC's investigation will be outlined in an upcoming edition of the Morbidity and Mortality Weekly Report (MMWR).
The FDA letter to health professionals, which is available at http://www.cfsan.fda.gov/~dms/inf-ltr3.html, provides recommendations for minimizing the risk in those circumstances when a powdered formula must be used for premature or immuno-compromised infants.
FDA urges health care providers to report adverse events associated with the
use of infant formulas as soon as possible to FDA's MedWatch program by calling
their toll-free number (1-800-332-1088) or through the Internet (http://www.fda.gov/medwatch).
Healthcare providers should report invasive disease in infants due to
E. sakazakii, particularly bloodstream infection or meningitis with onset
in the healthcare setting, to CDC's Division of Healthcare Quality Promotion
(1-800-893-0485).
FDA and CDC will continue their efforts to prevent E. sakazakii infections
associated with powdered infant formula.
###
Office
of Public Affairs
Web page uploaded by tg 2002-APR-12.